Mother-to-child Hepatitis D Transmission

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

54 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-10-31

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

HBV can be transmitted from mother-to-child, with a risk increasing according to maternal HBV DNA during pregnancy. HDV is a defective virus using HBs Ag for its own replication. Nucleosides analogues have only a minor impact on quantitative HBs Ag level. Data about vertical HDV transmission are old, justifying a new study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Hepatitis B Virus Mother-to-child Transmission by Serovaccination.

NCT01810835

Hepatitis B

COMPLETED

Clinical Study on the Effect of IVF-ET on Mother-to-child Transmission of Hepatitis B Virus

NCT03932851

Pregnancy

UNKNOWN

Registry-based Study in Patients With Hepatitis D Virus (HDV) Infection in China

NCT05451082

Hepatitis D

NOT_YET_RECRUITING

Seroepidemiologic Study of Spermatozoal Transmission of Hepatitis B Virus (HBV)

NCT01574521

Hepatitis B

COMPLETED

A Study of the Interruption on the Mother-to-child Transmission of Hepatitis B Virus （HBV MTCT）in Newborns at High Risk

NCT02901418

Chronic Hepatitis B

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hepatitis B Virus (HBV) can be transmitted from mother-to-child, with a risk increasing according to maternal HBV DNA viral load during the last trimester of pregnancy. Nucleosides analogues, lamivudine, telbivudine, or nucleotides analogues, tenofovir DF decrease HBV mother-to-child transmission risk, and are recommended in Guidelines (EASL 2012) for pregnant women with HBV DNA above 1,000 000 I.U/mL. HDV is a defective virus using HBs Ag for its own replication. HDV-HBV co-infection is a re-emerging infectious disease in western countries, due to immigration of people coming from endemic areas. Nucleosides analogues have only a minor impact on quantitative HBs Ag level (Boyd A et al. AIDS Research and Human Retroviruses 2013). Data about vertical HDV transmission are old (Rizzetto, et al. J Med Virol 1982), before a large use of nucleosides/nucleotides analogues in HBV infected pregnant women, justifying a new study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis D Transmission

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children born to HBV-HDV women

Children born to HBV-HDV co-infected women will be checked for:

* HDV antibodies
* if positive, HDV RNA

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* children born in the Maternity Department, Lariboisiere Hospital,
* from HBV-HDV co-infected women
* with a positive HDV RNA during pregnancy in the pregnant woman